Data from the STRATIS registry presented at the Society of NeuroInterventional Surgery annual meeting (SNIS; 25–28 July, Boston, USA) show that the transfer of stroke patients from one hospital to another is responsible for delays in revascularisation and suggest that there may be a place for bypassing closer hospitals for one that is capable of administering mechanical thrombectomy. The data were presented by Michael Froehler (Vanderbilt University Medical Center, Nashville, USA).
Diseased blood vessels in the brain itself may contribute more significantly to Alzheimer’s disease dementia than was previously believed, according to new study results published in The Lancet Neurology.
A new study, published in The Journal of Pain, has shown that transcranial magnetic stimulation (rTMS) administered to the scalp can stimulate the brain and provide significant reductions in phantom limb pain
InSightec has signed a strategic agreement with Siemens Healthineers. The strategic collaboration will involve the development of compatibility between Exablate Neuro and Siemens 1.5T and 3T clinical magnetic resonance imaging systems, Magnetom Aera and Skyra.
Medtronic has received CE mark for SureTune2 software, which is designed to provide patient-specific visualisation to help physicians make decisions on how to program their patient’s deep brain stimulation therapy. SureTune2 is currently not approved in the USA.
Boston Scientific Corporation has acquired Cosman Medical a privately-held manufacturer of radiofrequency ablation systems. According to a press release, the Cosman Medical team and products will become part of the Boston Scientific Neuromodulation business.
The US Food and Drug Administration FDA has allowed marketing of two Trevo Stryker Neurovascular clot retrieval devices as an initial therapy for ischaemic strokes to reduce paralysis, speech difficulties and other stroke disabilities.
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, has entered into an agreement with InNeuroCo for exclusive US and European distribution rights for intermediate catheters that are designed to enable minimally invasive treatment of haemorrhagic stroke. The announcement was made at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting.
According to an email from the consumer watchdog, the document is intended to clarify “how the FDA determines that real-world data may be sufficient for use in premarket and postmarket regulatory decisions, without changing the evidentiary standards we use to make those decisions.”
Although subarachnoid haemorrhage is more common among women than they are among men, the reasons for this difference were unclear. While smoking is the main risk factor, this study examined the association between smoking habits and subarachnoid haemorrhage in a large prospective study.
Cefaly has announced that its eponymous Cefaly device—which is a US Food and Drug Administration (FDA)-approved external trigeminal nerve stimulation device for the prevention of frequent episodic migraine attacks—has been revamped.
Penumbra has launched its new ACE 68 reperfusion catheter in the USA. The catheter is part of the Penumbra System, and was launched at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting in Boston, USA.
Hypertension remains the single most important modifiable risk factor for stroke, and the impact of hypertension and nine other risk factors together account for 90% of all strokes, according to an analysis of nearly 27000 people from every continent in the world (INTERSTROKE), published in The Lancet.
Penumbra has announced its schedule of key events at the Society of NeuroInterventional Surgery (SNIS) 13th Annual Meeting (July 25-28 2016, Boston, USA). These events include the presentation of the results of the randomised controlled clinical trial for the company’s next generation stent retriever, the Penumbra 3D revascularisation device.
Mentice has received a grant from the Swedish government agency for innovation, Vinnova, to develop a simulation-based training system including validated metrics capable of assessing proficiency in treatment of acute ischaemic stroke.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos